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Summary This study aimed at isolating Trypanosoma brucei gambiense from human African
trypanosomiasis (HAT) patients from south Sudan. Fifty HAT patients identiﬁed during active
screening surveys were recruited, most of whom (49/50) were in second-stage disease. Blood
and cerebrospinal ﬂuid samples collected from the patients were cryopreserved using Triladyl®
as the cryomedium. The samples were stored at −150 ◦C in liquid nitrogen vapour in a dry
shipper. Eighteen patient stabilates could be propagated in immunosuppressed Mastomys
natalensis and/or SCID mice. Parasitaemia was highest in SCID mice. Further subpassages
in M. natalensis increased the virulence of the trypanosomes and all 18 isolates recovered
from M. natalensis or SCID mice became infective to other immunosuppressed mouse breeds.
A comparison of immunosuppressed M. natalensis and Swiss White, C57/BL and BALB/c
mice demonstrated that all rodent breeds were susceptible after the second subpassage
and developed a parasitaemia >106/ml by Day 5 post infection. The highest parasitaemias
were achieved in C57/BL and BALB/c mice. These results indicate that propagation of T. b.
gambiense isolates after initial
be done in a range of immunosu
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l Medicine and Hygiene. Published by Elsevier Ltd. All rights
. Introductionfrican sleeping sickness (or human African trypanosomiasis
HAT)) is endemic in 36 countries in sub-Saharan Africa. It
s estimated that 60million people are at risk of infection,
hat 500 000 people are already infected and approximately
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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gFigure 1 Study site in Western Equatoria in south Sudan. : t
50 000 die every year (WHO, 2004). The disease is caused by
Trypanosoma brucei rhodesiense and T. b. gambiense. The
former causes an acute disease in Eastern Africa, whilst T.
b. gambiense generally causes a chronic disease in Western
and Central Africa. In Sudan, HAT due to T. b. gambiense
is highly endemic, with an estimated 1—2million people at
risk of infection and thousands of people infected.
Control of the disease relies mainly on chemotherapy.
The drugs used in Sudan are pentamidine for ﬁrst-stage
disease and melarsoprol and eﬂornithine for second-stage
disease. Melarsoprol is normally the ﬁrst-line drug for treat-
ment of second-stage disease. In recent years, high rates
of melarsoprol treatment failure (>20%) have been reported
in T. b. gambiense-endemic areas in Uganda, Angola and
Sudan (Burri and Keiser, 2001; Legros et al., 1999; Moore
and Richer, 2001). Additionally, a high fatality rate follow-
ing melarsoprol treatment has been noted. This has led to a
change of treatment policy and since September 2001 eﬂor-
nithine became the ﬁrst-line drug for second-stage disease
in Ibba Hospital (Me´dicins Sans Frontie`res, 2002).
The role of resistant trypanosomes in treatment failures
is not well understood, mainly because of a lack of T. b. gam-
biense isolates available from various endemic countries.
One reason for this is the difﬁculty of isolating this try-
panosome species and propagating it in laboratory rodents
(Brun et al., 2001). The purpose of this study was to isolate
T. b. gambiense from patients in Ibba Hospital and to evalu-
ate a new cryopreservation medium, Triladyl® (Maina et al.,
2006), under ﬁeld conditions. Additionally, the capacity of
different mouse breeds to develop a parasitaemia sufﬁcient
for laboratory investigations was studied.
2. Materials and methods2.1. Isolation of trypanosomes from patients
Active screening of HAT patients was carried out by Me´decins
Sans Frontie`res France (MSF-F) in Mundri and Maridi coun-
2
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figin of the patients; : Me´decins Sans Frontie`res laboratories.
ies, Western Equatoria, south Sudan (Figure 1). Diagnosis
as done serologically (Magnus et al., 1978) or parasitologi-
ally (trypanosomes detected either in lymph node aspirate,
enous blood or cerebrospinal ﬂuid (CSF)). The number of
hite cells in CSF was determined and used for classiﬁca-
ion of the stage of disease (WHO, 1998). Patients who had
een treated for HAT less than 12 months previously were
onsidered relapses or treatment failures.
In the hospital, patients were informed of the objectives
nd protocol of the study. To be included in the study, the
atients (or their guardians) had to give their consent (writ-
en/thumb print). The WHO and the Ministry of Health of
udan People’s Liberation Army (SPLA) approved the study
rotocol.
.1.1. Cryopreservation of patient stabilates
amples of 2—3ml of venous blood were collected from
atients into heparinised vacutainer tubes. Samples of 2ml
f CSF were also collected from two self-reporting patients
ttending the hospital. Trypanosomes in the samples were
oncentrated by centrifugation at 10 000 rpm for 10min and
he pellet was re-suspended in Triladyl® at a 1:1 ratio for
lood and 1:10 for CSF. Aliquots of 500l were then trans-
erred into Nunc® ampoules (Nunc, Roskilde, Denmark). Four
o ﬁve stabilates were prepared per patient and stored in a
iquid nitrogen dry shipper in the vapour phase at −150 ◦C.
ry shippers containing the stabilates were then transferred
rom the ﬁeld sites to the Trypanosomiasis Research Centre
TRC) in Kenya where primary propagation in rodents was
arried out.
.2. Propagation of Trypanosoma brucei
ambiense in laboratory rodents.2.1. Laboratory animals
astomys natalensis and Swiss White mice were bred at
RC. C57/BL and BALB/c mice, respectively, were purchased
rom the International Livestock Research Institute (ILRI)
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nd the Kenya Medical Research Institute (KEMRI), both in
airobi, Kenya. Severe combined immunodeﬁcient (SCID),
3H and FVB mice were purchased from the Charles River
aboratories, Inc. (Munich, Germany). NMRI mice were pur-
hased from RCC Ltd. (Itingen, Switzerland). The animals
ere housed under conventional conditions and fed on com-
ercial pellets and water ad libitum.
All animals (except SCID mice) were immunosuppressed
y administration of cyclophosphamide at 300mg/kg body
eight applied intraperitoneally 1 day prior to infection and
ere treated every 10 days with 200mg/kg.
.2.2. Primary propagation in Mastomys natalensis and
CID mice
he presence and viability of trypanosomes in the stabi-
ates was determined by inoculating one stabilate into one
CID mouse and two immunosuppressed M. natalensis. The
tabilates were thawed rapidly in a water-bath at 37 ◦C
nd immediately injected intraperitoneally into the rodents.
arasitaemia was monitored every other day for 60 days
y examination of tail blood using the haematocrit cen-
rifugation technique (HCT) and/or the method of Herbert
nd Lumsden (1976). Parasitaemic animals were euthanised
sing CO2 and blood was collected by cardiac puncture. The
nfected blood from the ﬁrst passage was cryopreserved in
riladyl® and stored in liquid nitrogen. Successful stabilates
ere given an isolation code different from the original
atient stabilate.
Rodents that remained aparasitaemic for 60 days after
noculation with cryopreserved material were euthanised
nd blood was collected by cardiac puncture. If no parasites
ould be detected using the HCT method, another two M.
atalensiswere inoculated with another duplicate stabilate.
.2.3. Susceptibility of various strains of mice to
rypanosoma brucei gambiense isolates
he growth pattern of ﬁve randomly selected isolates
as determined in C57/BL, BALB/c, Swiss White, NMRI,
3H and FVB mice as well as in M. natalensis. Prior to
hat, parasites from the primary propagation were pas-
aged twice in M. natalensis. Trypanosomes were harvested
rom a donor M. natalensis and inoculated into groups of
our animals (4× 105 trypanosomes/mouse) of the different
ouse breeds. Thawing of the stabilates, inoculation and
arasitaemia determination were performed as described
arlier.
.3. Genotypic characterisation
rypanosomes (passage 1) were puriﬁed using an anion
xchange column (Lanham and Godfrey, 1970) and DNA was
xtracted using the Puregene DNA extraction kit (Gentra
ystems, Minneapolis, MN, USA) as previously described by
atovu et al. (2001a).
Ampliﬁcation of the serum resistance-associated (SRA)
ene and the T. b. gambiense-speciﬁc glycoprotein (TgsGP)
ene was done as previously described by Radwanska et
l. (2002a, 2002b). However, for both genes a nested PCR
as performed. For SRA, the two sets of primers used
ere: SRA-out-s (5′-CCTGATAAAACAAGTATCGGCAGCAA-3′)
nd SRA-out-as (5′-CGGTGACCAATTCATCTGCTGCTGTT-3′);
3
p
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nd SRA-inner-s (5′-ATA GTG ACA TGC GTA CTC AAC
C-3′) and SRA-inner-as (5′-AAT GTG TTC GAG TAC TTC
GT CAC GCT-3′). For the TgsGP gene, the primer pairs
ere: TbsGP-outer-s (5′-GCGTATGCGATACCGCAGTAA-3′) and
bsGP-outer-as (5′-GCTTCAACCGCCGCTGCTTCTA-3′); and
bsGP-s (5′-GCTGCTGTGTTCGGAGAGC-3′) and TbsGP-as (5′-
CCATCGTGCTTGCCGCTC-3′).
For control PCRs, the actin gene was ampliﬁed
sing primers act-s (5′-CCGAGTCACACAACGT-3′) and act-as
5′-CCACCTGCATAACATTG-3′). The ampliﬁcations were per-
ormed in 50l of reaction mixture containing PCR buffer
Qiagen, Basel, Switzerland), 200mM of the four dNTPs,
M of each primer and Taq polymerase in a PTC 200 Peltier
hermocycler (MJ Research, Waltham, MA, USA) under the
ollowing conditions: initial denaturation at 94 ◦C for 3min,
0 cycles of 94 ◦C for 45 s, 62 ◦C (55 ◦C for actin) for 45 s and
2 ◦C for 120 s, followed by a ﬁnal extension for 10min and
apid cooling at 4 ◦C.
Eight microlitres of the PCR product were analysed by
lectrophoresis in a 1.25% agarose gel. The gels were stained
ith ethidium bromide (0.2g/ml) and visualised under UV
ight.
.3.1. Sequencing of TgsGP
or sequencing, two independent PCR reactions were
ooled, puriﬁed using QIAquick columns (Qiagen) and
equenced with the Big Dye Terminator kit (Applied Biosys-
ems, Foster City, CA, USA). The products were run at the
omputational and Molecular Population Genetic Laborato-
ies (CMGP, Zoology Department, University of Bern) on an
BI sequencer.
. Results
.1. Patients
lood samples were collected from 50 patients from Mundri
46), Maridi (2), Yambio (1) and Juba (1) counties (Figure 1).
he mean age of the patients was 24 years (range 0.25—62
ears) with >90% below 40 years of age. Most patients
49/50) were in the second stage of the disease, which
as mainly based on a white cell count >5 cells/l rather
han the presence of trypanosomes in the CSF. Seven of the
atients had previously been treated (7—12 months before):
our with eﬂornithine (at 400mg/kg/day for 14 days) and
hree with pentamidine (4mg/kg/day for 7 days).
Forty-two patients were parasite positive in the blood
nd eight were aparasitaemic but card agglutination test
or trypanosomiasis (CATT) positive at a 1:4 dilution. Sam-
les of CSF were only collected from two patients attending
he hospital for passive screening. For all other patients, a
umbar puncture had already been done in the ﬁeld during
ctive screening and for ethical reasons a second lumbar
uncture was not performed in the hospital..2. Primary propagation of stabilates from
atients
f the 50 blood samples inoculated into M. natalensis and
CID mice, 18 caused patent infections. The two CSF sam-
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Table 1 Trypanosoma brucei gambiense isolates from Mundri county that could be propagated in laboratory rodents
Patient
stabilate
Isolate no. Patient data Proof of infection and staginga Primary propagation in rodentsb
Bomas
(village)
Age
(years)
Sex Blood/
lymph
CSF CSF
(cells/l)
SCID mice M. natalensis
Pre-patent
period
Parasitaemia at freezing
(days post infection)
Pre-patent
period
Parasitaemia at freezing
(days post infection)
I04008 Mundri 01 Midi 19 F + — 8 7 1.6× 107 (7) 12 +++ (14)
I03037 Mundri 02 Amandi 12 F + — 49 7 1.6× 107 (7) 8 +++ (10)
K03028 Mundri 03 Nyau 1 25 M + — 6 11 1.6× 107 (12) 4 +++ (6)
K03048 Mundri 04 Buangyi 20 M + — 58 4 1.6× 107 (6) 4 2.5× 104 (5)
K03051 Mundri 05 Nyau 1 23 M ND — 50 7 8× 106 (14) 23 ++ (26)
K03030 Mundri 06 Goribalan 21 F + — 4 11 1× 106 (21) 9 ++ (11)
K03042 Mundri 07 Nyau 1 20 M + — 10 14 ++ (14) 10 ++ (12)
I04019 Mundri 08 Lazoh 10 M + — 17 13 + (13) 21 3.2× 107 (25)
K03043 Mundri 09 Wiri Lui 6 M + — 9 5 3.2× 107 (9) — —
I04015 Mundri 10 Singo 12 M + — 104 11 1.6× 107 (11) — —
K03045 Mundri 11 Nyau 1 12 M ND — 8 17 1.0× 106 (22) — —
I04022 Mundri 12 Lazoh 9 F + — 8 16 2.5× 104 (24) — —
K03010 Mundri 13 Mundri 27 M + — 61 — — 3.5 8× 106 (5)
I04021 Mundri 14 Gingo 23 F + — 45 — — 18 2× 106 (21)
I03030 Mundri 15 Lazoh 12 F + — 8 — — 6 2.5× 104 (7)
K03044 Mundri 16 Nyau 1 12 F + — 20 — — 11 +++ (13)
K03032 Mundri 17 Singirigwa 22 F + + 783 — — 17 +++ (18)
K03054 Mundri 18 Moto 25 M + — 22 — — 11 + (13)
CSF: cerebrospinal ﬂuid; ND: not done.
a Trypanosomes were detected by examination of blood using haematocrit centrifugation technique (HCT) method and/or lymph node aspirate and by examination of CSF. Staging of
disease was done by examination of CSF for the presence of trypanosomes and by white blood cell count in CSF (>5 cells/l = second-stage disease).
b Primary propagation was done in immunosuppressed Mastomys natalensis and SCID mice. Parasitaemia in rodents was estimated by the method of Herbert and Lumsden (1976) or, for
lower parasitaemia, by the HCT method.
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les did not lead to patent parasitaemia in the rodents.
atient stabilates that could be successfully propagated in
he rodents were designated with the name ‘Mundri’ (the
ame of the county where all the patients came from) and
consecutive number; furthermore, they were termed iso-
ates (Table 1). A slightly higher recovery was obtained in
. natalensis (14/18) compared with SCID mice (12/18).
nly 8/18 stabilates could be propagated in both rodents.
he stabilates had a similar pre-patent period in SCID mice
10.25± 4.26 days) and M. natalensis (11.25± 6.3 days).
owever, in M. natalensis only 3/14 stabilates developed a
arasitaemia of ≥106/ml, whereas in the SCIDmice 9/12 sta-
ilates reached that level of parasitaemia. Details of these
8 isolates are shown in Table 1.
.2.1. Determination of the suitability of Swiss White
ice for patient stabilates
nly ﬁve (I03030, I03037, K03048, K03045 and K03051) of
he 18 patient stabilates that could be propagated in either
mmunosuppressedM. natalensis and/or in SCID mice caused
atent infection in immunosuppressed Swiss White mice.
he susceptibility of Swiss White mice was much lower com-
ared with that of M. natalensis. The parasitaemias in Swiss
hite mice were generally low (apart from K03048) and
ould only be detected by the HCTmethod. For one stabilate
K03051), parasitaemia was sporadic and inconsistent..2.2. Susceptibility of mice to secondary propagation
f Trypanosoma brucei gambiense
ll 18 isolates (Mundri 1 to 18, ﬁrst passage) inoculated
nto immunosuppressed Swiss White mice caused patent
T
f
r
f
g
Table 2 Comparison of the growth characteristics of Trypanos
immunosuppressed with cyclophosphamide 300mg/kg prior to infe
(passage 3) by the intraperitoneal route. Parasitaemia was monito
daysa
Isolate no. (patient stabilate) Rodent breed Pe
>
Mundri 02 (I03037)
C57/BL 4
BALB/c 4
Swiss White 5
Mastomys natalensis 6
Mundri 05 (K03051)
C57/BL 5
BALB/c —
Swiss White 5
M. natalensis 6
Mundri 09 (K03043)
C57/BL 5
BALB/c 5
Swiss White 5
M. natalensis 5
Mundri 13 (K03010)
C57/BL 5
BALB/c 5
Swiss White 5
M. natalensis 5
Mundri 17 (K03032)
C57/BL 5
BALB/c 6
Swiss White 6
M. natalensis 5
a Data shown are the mean of four animals.N.W.N. Maina et al.
nfection, with a pre-patent period of 4 days. Most of the
solates (11/18) caused low and inconsistent parasitaemias
<104/ml), but the remaining isolates (Mundri 02, 03, 04, 06,
8, 14 and 17) grew to higher parasitaemia with levels >106
rypanosomes/ml (data not shown).
The growth patterns of ﬁve randomly selected isolates
passage 4) were compared in immunosuppressed C57/BL,
ALB/c and Swiss White mice and M. natalensis (Table 2).
he parasites were infective for all rodents used, with a
imilar pre-patent period of 3 days and a parasitaemia
106 trypanosomes/ml by Day 5. There was variation in
he growth pattern between the isolates and between
odent breeds. For all ﬁve isolates, the highest parasitaemia
>5× 107 trypanosomes/ml) was noted in C57/BL mice.
verall, C57/BL and BALB/c mice sustained higher para-
itaemias (>106/ml) for several days compared with Swiss
hite mice or M. natalensis. In all isolates, the para-
itaemias dropped to undetectable levels by Day 16 post
nfection. Very few animals (4/80) died during the 60-day
bservation period. In NMRI, C3H and FVB mice, para-
itaemia was always very low and far below the parasitaemia
n C57/BL and BALB/c mice (data not shown).
.3. Genotypic characterisationrypanosoma brucei subspecies-speciﬁc genotyping was per-
ormed by PCR using the SRA gene as a marker for T. b.
hodesiense (Radwanska et al., 2002a) and the TgsGP gene
or T. b. gambiense (Berberof et al., 2001). The marker
enes were ampliﬁed from genomic DNA by nested PCR
oma brucei gambiense in different rodents. Animals were
ction. Each animal was inoculated with 4× 104 trypanosomes
red every other day by examination of the tail blood for 20
riod with parasitaemia
106/ml (mean duration) (days)
Highest parasitaemia
(days post infection)
—16 (12.5) 2.5× 108 (7)
—14 (4.25) 1.6× 107 (8.5)
—7 (2) 0.8× 107 (6)
—8 (2) 3.2× 106 (7)
—9 (4.66) 5.0× 107 (7.66)
—
—16 (4.5) 1.3× 107 (8.25)
—7 (1.5) 4.6× 106 (6)
—8 (3.75) 7.4× 107 (6.75)
—9 (4.75) 6.4× 107 (7.25)
—7 (3) 1.4× 106 (6.5)
—7 (3) 0.8× 107 (6)
—14 (6.25) 1.5× 108 (7.5)
—14 (6.26) 8.9× 107 (7.5)
—7 (1.75) 3.2× 106 (6.25)
—7 (2.5) 1.1× 107 (5)
—18 (13) 5.0× 108 (14)
—9 (3.33) 5.0× 107 (7.33)
—7 (2) 5.0× 106 (6.5)
—7 (3) 6.4× 107 (7)
T. b. gambiense isolated from sleeping sickness patients
Figure 2 Genotypic characterisation: ampliﬁcation of the
Trypanosoma brucei gambiense-speciﬁc glycoprotein gene
(TgsGP, top) and the serum resistance-associated gene (SRA,
bottom) in trypanosomes isolated from human African try-
panosomiasis patients. All 18 stabilates gave the same result,
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Rtherefore only 6 of them are shown here (lanes 1—6). Try-
panosoma b. rhodesiense STIB 704 (lane 7) and T. b. gambiense
STIB 754 (lane 8) were used as reference.
and were analysed on agarose gels (Figure 2). All isolates
tested were positive for TgsGP and negative for SRA. To ver-
ify that the correct gene was ampliﬁed, PCR products were
directly sequenced. Apart from a few silent mutations, the
obtained sequence (GenBank accession no. DQ224158) was
identical to that published for TgsGP (GenBank accession
no. AJ277951), conﬁrming that the isolated trypanosomes
were indeed T. b. gambiense.
4. Discussion
This is the ﬁrst report of successful isolation of T. b. gambi-
ense from patients in south Sudan. Eighteen viable isolates
could be cryopreserved under ﬁeld conditions using the new
cryomedium Triladyl® (Maina et al., 2006). In previous stud-
ies, a low recovery rate or complete loss of T. b. gambiense
populations following cryopreservation in medium contain-
ing 10% glycerol have been reported (Brun et al., 2001;
Matovu et al., 2001b). The recovery rate achieved of 43%
is very satisfactory and may be attributed to the superior
cryopreservation medium Triladyl®.
Viability of the isolates in rodents depended on the
degree of parasitaemia in the patients. Parasitaemia in
patients was always low and only detectable by HCT; in eight
patients parasites were not detectable at all although the
patients were CATT positive. Earlier reports also noted the
poor infectivity of T. b. gambiense for laboratory rodents,
leading to a low isolation success (Aerts et al., 1992; Dukes
et al., 1989).
In the current study, we used the African rodent M. natal-
ensis (immunosuppressed) for primary propagation of the
patient stabilates on a comparative basis with SCID mice,
which have no functional T- and B-lymphocytes (Bosma et
al., 1983). Mastomys natalensis was reported to be a bet-
ter model for T. b. gambiense than rats and mice (Mehlitz,
1978) and has been extensively used for propagation studies
(Aerts et al., 1992; Dukes et al., 1989; Gibson et al., 1978;
Matovu et al., 2001b; Zillmann and Mehlitz, 1979). Inoue et
al. (1998) ﬁrst described the high susceptibility of SCID mice
to T. b. gambiense isolates, a ﬁnding that was conﬁrmed in
our study. However, the use of SCID mice is restricted by the
high cost of the mice as well as availability. On the other
A
W
T545
and, breeding colonies of M. natalensis are already in place
t institutes in East Africa.
Normal inbred or outbred laboratory mice have gener-
lly not been found to be susceptible to T. b. gambiense
solates, although they can easily be infected with T. b.
hodesiense trypanosomes. However, we found that follow-
ng immunosuppression different breeds of laboratory mice
ould be infected with the second or third passage of our
undri T. b. gambiense isolates. Even stabilates prepared
irectly from patients were infective for immunosuppressed
wiss White mice, although with a lower success rate (5/18)
ompared with M. natalensis (14/18) or SCID mice (12/18).
owever, after a second passage, all 18 isolates were infec-
ive for immunosuppressed Swiss White mice and 7 of them
eveloped a parasitaemia >106/ml. In other mouse strains
C57/BL, BALB/c, NMRI, C3H and FVB), the parasitaemia
as very low, except for the three isolates K03028, K03048
nd K03043, which reached parasitaemias >105/ml in C57/BL
nd BALB/c by Day 14 post infection. Passaging the isolates
t least three times increased their virulence, resulting in
arasitaemias >107/ml.
In conclusion, we recommend that infected blood sam-
les from T. b. gambiense patients should be cryopreserved
n Triladyl® medium. Primary propagation and subsequent
ubpassage should be done in immunosuppressed M. natal-
nsis or in SCID mice. Further subpassages can then be
one in immunosuppressed laboratory mice (e.g. C57/BL
r BALB/c). Available mouse breeds should be screened
ollowing immunosuppression with cyclophosphamide at
00mg/kg prior to infection and repeated once per week at
00mg/kg. This propagation scheme is efﬁcient as well as
conomical. However, it must be kept in mind that repeated
assage through rodents can lead to parasite strain selec-
ion, thus the results obtained must not be interpreted as
epresenting the true strain diversity in the human popula-
ion. The proposed scheme will allow the characterisation
f T. b. gambiense from various hot spots of Central Africa
nd therefore facilitate the monitoring of drug-resistant try-
anosomes. These new T. b. gambiense isolates from Sudan
re a unique source for further scientiﬁc investigations.
heir characterisation, especially for drug sensitivity, will
elp to elucidate the cause of the high melarsoprol treat-
ent failure rates reported from the area.
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